NK-cell therapy in resistant MDS, AML

Print Friendly, PDF & Email


Natural killer cell
destroying a cancer cell
Image by Joshua Stokes
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). NK-cell therapy elicited responses in 6 of the 16 patients studied and provided a bridge... [Read Article]
Print Friendly, PDF & Email

Azacitidine now available in China

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with intermediate-2/high-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20% to 30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). Azacitidine for injection is marketed in... [Read Article]
Print Friendly, PDF & Email

EC grants orphan designation to gilteritinib for AML

Print Friendly, PDF & Email


AML cells
The European Commission (EC) has granted orphan designation to gilteritinib for the treatment of patients with acute myeloid leukemia (AML). Gilteritinib is an investigational compound that has demonstrated inhibitory activity against FLT3 internal tandem duplication, FLT3 tyrosine kinase domain, and the AXL receptor. Astellas Pharma Inc. is currently investigating gilteritinib in... [Read Article]
Print Friendly, PDF & Email